Democrats are currently attempting to pass the Build Back Better Act, which amalgamates President Biden’s first-term domestic policies and runs to 2,465 pages, through the budgetary process of reconciliation.
It may not pass, at least not immediately. But whatever the outcome of the current legislative process, the pharmaceutical industry knows that H.R. 3 — the component of the reconciliation bill which aimed at addressing a perception that prescription drug prices are too high — is unlikely to drop off the agenda. Continue reading